MESSAGE FROM THE GROUP CHAIR

November 2014 marked the end of the third full year of operation for the Alliance. It is truly amazing to consider how far we have come since then. We competed successfully for funding of the NCI National Clinical Trials Network (NCTN) Operations Group, Statistics and Data Management Center, and NCI Clinical Oncology Research Program (NCORP) awards, and now have a NCTN Biorepository grant proposal under review.

The Alliance currently has a total of 87 Main Member Institutions, 18 Network Lead Academic Participating Sites and 35 National Clinical Oncology Research Program Sites. A total of 27 trials opened to accrual under new Alliance numbers, with more than 30 new studies currently in various stages of development. In addition to being highly visible in presenting data at national and international meetings, Alliance committees published 187 abstracts and 217 manuscripts over the past three years.

Finally, in 2014 the Alliance for Clinical Trials in Oncology Foundation launched a new enterprise, known as Alliance Foundation Trials, which provides our researchers and patients with access to new studies in collaboration with partners outside of the NCI. None of these accomplishments were easy, because they were achieved in the midst of sacrifices necessitated by difficult changes in NCI policies and funding. As a result, Alliance members can take particular pride in this clear evidence that we can succeed in doing whatever it takes to achieve better results for our patients.

There are so many people to thank for the great success of the Alliance in its first three years – far too many to list here. Instead, your names can be found all throughout the 2014 Alliance Meeting Book (on the Alliance website under the 2014 Group meeting).

I look forward to even greater success to follow in the coming new year.

Monica M. Bertagnolli, MD
Alliance Presents Research Honors, Awards to Outstanding Junior Investigators

The Alliance for Clinical Trials in Oncology Foundation annually invites applications for grants to support research activities of oncology junior faculty working at Alliance institutions. This research includes studies that assess interventions in cancer patients and/or examines biological specimens obtained from cancer patients. This year, with the support of Genentech Inc. and Millennium Pharmaceuticals/The Takeda Oncology Company, the foundation presented awards to three young investigators during the 2014 Alliance Fall Group Meeting Plenary Session in Chicago, IL.

2014 Alliance Scholar Award in Honor of Emil “Tom” Frei III, MD
funded by the Millennium Pharmaceuticals/The Takeda Oncology Company

Himisha Beltran, MD
Assistant Professor of Medicine in the Division of Hematology/Oncology
Weill Cornell Medical College
“Impact of Therapy on Modulation of Neuroendocrine-Associated Gene Expression in Patients with High Risk, Localized Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy”

2014 Alliance Scholar Awards
sponsored by Genentech, Inc.

Sandra P. D’Angelo, MD
Assistant Professor of Medicine
Memorial Sloan Kettering Cancer Center
“Identifying Biomarkers Predictive of Response to Nivolumab +/- Ipilimumab in Patients with Metastatic Sarcoma”

sponsored by Millennium Pharmaceuticals/The Takeda Oncology Company

Peter Martin, MD
Assistant Professor of Medicine in the Division of Hematology/Oncology
Weill Cornell Medical College
“Overcoming Resistance to Cell Signaling Inhibitors in Mantle Cell Lymphoma”
Alliance Selects Three ‘Best of’ for Third Annual Published Manuscripts Book

The Alliance Publications Committee, in collaboration with the Group Chair’s Office, continues a yearly tradition to highlight and share the Group’s notable publications. Each year, the committee produces a booklet for the Alliance Fall Group Meeting that contains abstracts of Alliance original manuscripts published in the preceding 12 months. The committee also selects the three most significant manuscripts from that time period, based on review by Alliance scientific leadership as well as a separate review panel. Each nominated manuscript must satisfy at least one of the following criteria: potential to change the standard of care; potential to change the way clinical trials are designed and/or executed; and potential to change our understanding of cancer biology. At least one nomination has to have a junior investigator as first author (one who has completed training within the previous eight years), if such a manuscript had been published and met the qualifications.

The 2013-2014 “Best of” Alliance Published Manuscripts reflect original manuscripts published by the Alliance between September 1, 2013 and August 31, 2014. This year’s recipients are:

(Guido Marcucci, MD)
Professor of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, and Pharmaceutics, Division of Hematology
The Ohio State University
“Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score”

(Guido Marcucci)

(Hiran C. Fernando, MD)
Chief, Division of Thoracic Surgery; Director, Center for Minimally Invasive Esophageal Surgery; and Professor of Surgery
Boston University School of Medicine
“Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non-Small Cell Lung Cancer”

(Hiran C. Fernando)

(Rebecca S. Heist, MD, MPH)
Assistant Professor in Medicine
MGH Cancer Center, Massachusetts General Hospital
“CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of advanced Non-Small-Cell Lung Cancer”

(Rebecca S. Heist)
Long-time Alliance Investigator Receives Schilsky CALGB Achievement Award

The Richard L. Schilsky Cancer and Leukemia Group B Achievement Award is presented by the Alliance for Clinical Trials in Oncology Foundation for contributions to cancer research. Established in 2010 to recognize the 15-year tenure of Dr. Schilsky as Group Chair of CALGB, the award acknowledges the significant contributions of an individual to cooperative group research. Each year, the Alliance seeks to identify and honor the talented people responsible for its success. The award was presented during the 2014 Alliance Fall Group Meeting Plenary Session in Chicago, IL, and is made possible through generous donations from Alliance members and industry supporters.

2014 Richard L. Schilsky CALGB Achievement Award

Nancy L. Bartlett, MD
Professor of Medicine, Division of Oncology
Koman Chair in Medical Oncology
Alvin J. Siteman Cancer Center
Washington University School of Medicine

Dr. Bartlett is well-recognized as one of the top lymphoma researchers in the U.S., and is specifically regarded among the leading Hodgkin lymphoma experts in the world.

She has been a faculty member at Washington University and member of Cancer and Leukemia Group B/Alliance since 1994. In 1998, she became the Washington University Principal Investigator, a member of the Board of Directors and the Lymphoma Committee. She served on the Executive Committee from 2000 to 2002 and became Vice Chair of the Lymphoma Committee in 2003. Dr. Bartlett has participated in the design, conduct, or analysis of every CALGB/Alliance study conducted by the Lymphoma Committee over this time period and has co-authored 21 publications of Alliance studies (five as first or senior author) that reflect her significant scientific and accrual contributions.

A few of her important research contributions include assessment of combined-modality treatment in patients with HL, studies of radio-immunotherapy, establishing an outpatient regimen of gemcitabine/vinorelbine/liposomal doxorubicin as a standard of care for relapsed HL, evaluation of positron emission tomography (PET) in HL, and key trials of the antibody-drug conjugate brentuximab vedotin that have had a major impact on HL therapy.

After Dr. Bartlett received her award during the 2014 Alliance Fall Group Meeting Plenary Session, she presented a lecture entitled “The Tale of Stanford V: A Successful Failure 1989-2014.” The lecture covered her journey to become an accomplished investigator, beginning as a fellow at Stanford, then joining the Washington University faculty and the CALGB, on to becoming the CALGB PI, then serving as Vice Chair of the Lymphoma Committee, and finally co-authoring 24 publications (3 as first author, 3 as senior author and 18 as middle author).
Prominent Researchers Deliver Key Lectures at Alliance Annual Fall Meeting

Four prominent cancer researchers were selected to present plenary talks and named lectures during the 2014 Alliance Fall Group Meeting.

**Plenary Session: Jan C. Buckner, MD**, Director/PI of the Alliance Cancer Control Program. “Transitioning from NCI CCOP to NCORP Grants” was the title and focus of Dr. Buckner’s presentation. He discussed the Alliance/NCI Community Oncology Research Program (NCORP) research base grant, key accomplishments, and future program plans. The NCORP, which was launched by the NCI Division of Cancer Prevention in August, designs and conducts cancer prevention, control, screening and post-treatment surveillance trials, along with cancer care delivery research, including comparative effectiveness research. It also integrates disparities research questions into clinical trials and cancer care delivery research.

**Plenary Session: Michael J. Morris, MD**, Chair of the Alliance GU Committee and Professor of Medicine at Memorial Sloan Kettering Cancer Center. Dr. Morris presented “From Famine to Feast in Prostate Cancer: Defining a New Clinical, Regulatory, and Scientific Landscape.” He discussed recent advances in genitourinary cancers and highlighted promising agents in the field. He also reviewed in detail the GU committee’s newest trial, Alliance A031201, a phase III study that will evaluate hormonal therapies in patients with progressive metastatic castration-resistant prostate cancer (CRPC).

**American College of Surgeons Clinical Research Program Plenary Session: Elaine R. Mardis, PhD**, Co-Director and Professor of Genetics at The Genome Institute at Washington University in St. Louis. Dr. Mardis presented the lecture entitled “Genomic Analysis from Z1031 and Beyond.” Her research focus is in the application of next-generation sequencing to characterize cancer genomes and transcriptomes, and using these data to support therapeutic decision-making. She is also interested in facilitating the translation of basic science discoveries about human disease into the clinical setting.

**14th Annual Jimmie C. Holland Lecture: David Cella, PhD**, Chair of the Department of Medical Social Sciences and Director of the Center for Patient-Centered Outcomes at Northwestern University’s Feinberg School of Medicine. Dr. Cella research interests are in cancer communications, health disparities, outcome measures, quality of life, and psychological issues faced by patients with illness. Some of his most recent publications are focused on quality of life (QOL) research in patients with advanced cancers and specifically those with breast, ovarian or brain cancer. Dr. Cella presented “Quality of Life in Oncology Clinical Trials: 30 Years and Where Have We Come?”
Alliance Welcomes New Committee Chairs

The Alliance for Clinical Trials in Oncology Board of Directors has appointed four Alliance members to lead the following committees: Cancer Care Standards Development, Clinical Research Professionals, Leukemia and Leukemia Correlative Science.

John C. Byrd, MD
Chair – Alliance Leukemia Correlative Science Committee
Dr. Byrd is the D. Warren Brown Chair of Leukemia Research Professor of Medicine, and Director of the Division of Hematology at The Ohio State University. He is also the Associate Director of Translational Research for the OSU Comprehensive Cancer Center. A long-time contributor to the Cancer and Leukemia Group B and the Alliance recently serving as Co-Vice Chair of the Alliance Leukemia Committee, Dr. Byrd has a particular interest in research and treatment for chronic lymphocytic leukemia. He brings to this role a long history of funding through various NCI mechanisms, including the SPORE program.

Jennifer L. Dill, CCRP
Chair – Alliance Clinical Research Professionals
Ms. Dill is currently Manager of the Alliance Clinical Trials Program in Medical Oncology at the Washington University School of Medicine. She supervises a staff of 25 research coordinators who coordinate more than 200 National Clinical Trials Network trials. She is also involved in managing Washington University’s Lead Academic Participating Sites grant through the National Institutes of Health. Ms. Dill’s main goal for the committee is to enable CRPs to improve quality of protocol implementation and data management through increased educational and training opportunities both at Group meetings and on-line, ensuring all CRPs are trained and equipped to submit quality data for each clinical trial. Through quality data submission, the efficiency and efficacy of data submission and timeliness for data analysis can be improved.

Matthew H.G. Katz, MD, FACS
Chair – Alliance Cancer Care Standards Development
Dr. Katz is an Assistant Professor in the Department of Surgical Oncology, Division of Surgery, at the University of Texas MD Anderson Cancer Center. His clinical and research interests focus on patients with pancreatic cancer. He has extensive experience in the design and conduct of clinical trials and is currently the PI of an intergroup study of the effects of preoperative therapy on patients with advanced pancreatic cancer (Alliance A021101). He has published more than 80 original articles that have described novel multi modality treatment approaches for patients with this disease.

Guido Marcucci, MD
Vice Chair – Alliance Leukemia Committee
Vice Chair – Alliance Leukemia Correlative Science Committee
Dr. Marcucci is a Professor of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, and Pharmaceutics in the Division of Hematology at Ohio State University Comprehensive Cancer Center. Recently, he accepted a new position at the Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope, which he will begin soon. As Dr. Marcucci transitions to another institution, he has agreed to remain with the Alliance, and active participate in both leukemia and leukemia correlative committees. He will also continue in his role as a Co-Principal Investigator of the Alliance U10 award for Leukemia Translational Research.
Kandie Dempsey, DBA(c), MS, RN, OCN  
Chair – Alliance Clinical Research Professionals Committee

Ms. Dempsey’s career in oncology nursing has spanned more than 27 years, where she has served in various patient care provider and management leadership roles. Since 1998, she has served as lead CRP at Christiana Care Health Services’ Cancer Research Department at the Helen F. Graham Cancer Center & Research Institute in Newark, DE, providing oversight for the NCI CCOP (now NCORP), industry based and translational research programs. Appointed as a cadre member of the CALGB Clinical Research Associates Committee in 2000, Ms. Dempsey became committee chair three years later and served in that role through the transition to the Alliance. She completed 14 years of Alliance service this past November.

During her tenure, Ms. Dempsey developed, promoted and implemented training programs to enhance the skills and abilities of clinical research professionals from across the U.S., improving their overall knowledge and professionalism. The committee played a critical role in educating CRPs in clinical research methods, Alliance policies and procedures, NCI initiatives and Alliance scientific priorities and directions. Educational programs included disease-specific and administrative-related presentations that were a key underpinning to the success and quality of Alliance research. Ms. Dempsey has served on numerous national committees specific to oncology nursing and research including the NCI Cancer Genome Atlas Project, National Community Cancer Centers Program, National Surgical Adjuvant Breast & Bowel Project, Cancer Trials Support Unit and Oncology Nursing Society. In December 2014, she will earn a Doctorate in Business Administration.

Bettye L. Green, RN  
Vice Chair – Alliance Patient Advocate Committee  
Associate Director of Advocacy for the Alliance

Mrs. Green has had a long involvement with breast cancer advocacy activities, including work with the African American Breast Cancer Project, the American College of Surgeons Oncology Group, the American Association for Cancer Research, the National Action Plan on Breast Cancer, and the National Breast Cancer Coalition. She hails from South Bend, IN, where she has been a registered nurse for more than 30 years at Saint Joseph Regional Medical Center, recently serving as the Community Outreach Coordinator and Hospital IRB Coordinator. She has held the position of Institutional Review Board Chairperson of the Northern Indiana Cancer Research Consortium for more than eight years.

Mrs. Green is a 24-year breast cancer survivor, who entered the battle against breast cancer in 1990. She has done work in the area of protocol review, which has included grant review for the Department of Defense, AVON, NCI, California Breast Board and for the Komen Foundation. She was appointed to three committees in the President’s National Action Plan Against Breast Cancer. Mrs. Green has continuously fought to eradicate breast cancer and has been an educator, trainer, committee member for many groups and sought after meeting speaker.
Beyond the Alliance

**John C. Byrd, MD**
Dr. Byrd, D. Warren Brown Chair of Leukemia Research Professor of Medicine, and Director of the Division of Hematology at The Ohio State University, and his research team have received one of the Top 10 Clinical Research Achievement Awards in the U.S. for 2014 by the Clinical Research Forum for their study “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia.” Winning projects of the third annual awards program represent outstanding examples of research projects that benefit the health and well-being of the general public. Dr. Byrd is Chair of the Alliance Leukemia Correlative Science Committee.

**Michael A. Caliguiri, MD**
Dr. Caliguiri, Director of The Ohio State University Comprehensive Cancer Center and CEO of the James Hospital and Solove Research Institute, is the new Chair of the National Institute of Medicine’s (IOM) National Cancer Policy Forum. The forum serves as a focal point and trusted venue for the engagement of national leaders from multiple sectors working cooperatively to address high priority policy issues in the nation’s effort to combat cancer. Dr. Caliguiri is Study Chair of the CALGB Leukemia Tissue Bank, and the former Chair of the Leukemia Correlative Science Committee.

**NCI Awards Alliance Researchers $1.47M**

Alliance researchers at Washington University School of Medicine and the Siteman Cancer Center have been awarded $1.47 million to study whether a tumor’s DNA sequence can predict brain metastasis in patients with non-small cell lung cancer (NSCLC). **Mark Watson, MD, PhD**, Associate Professor of Pathology and Immunology, and **Ramaswamy Govindan, MD**, Professor of Medicine, received the five-year grant from the National Cancer Institute (NCI). They intend to use a tumor’s DNA sequence information not only to identify patients at risk but also to suggest which therapies are most likely to halt the process, according to Dr. Watson, the project leader.

In nearly half of all patients with NSCLC, the disease spreads to the brain. An estimated 224,000 people in the U.S. will be diagnosed with lung cancer this year, according to the NCI. Of them, about 88 percent will have non-small cell lung cancer.

To identify genomic predictors of metastasis, Drs. Watson and Govindan will directly compare the primary and metastatic cancers of patients with NSCLC. This will help the researchers to identify patterns of genomic changes that are specific to metastatic tumor cells found in the brain. These patterns of DNA sequence change will be used to develop a risk model for brain metastasis, which will be tested for its accuracy in several hundred additional lung cancer patients.

If the approach is successful, it could lead to the development of a tumor DNA test that would identify those lung cancer patients who are not at risk for brain metastasis and may not need additional treatment. More importantly, in those patients whose tumor DNA sequence predicts a high risk, it may identify new opportunities for effective therapies to halt the process.
Pioneer in Translational Research
M. Robert Cooper, MD, 1933-2014

Miles Robert Cooper, MD, a pioneer of translational research and a leader in medical research, died October 26. He was 81. Dr. Cooper served as Professor Emeritus of Internal Medicine, Section on Hematology/Oncology, and Director of Emeritus Affairs at the Wake Forest School of Medicine. He was also one of the founding members of the Cancer and Leukemia Group B (CALGB), a legacy group of the Alliance for the Clinical Trials in Oncology. He served as the Principal Investigator for Wake Forest and on the Board of Directors for 19 years, from 1979 to 1998, and as a member of the Minority Issues (one year, 1997) and Lymphoma (21 years, 1979-2000) committees.

Dr. Cooper was dedicated to cooperative group research, chairing important leukemia, lymphoma and myeloma studies (C7251, C7761 and C8514). He played a significant role as the CALGB led the way among the cooperative groups in the creation of centralized tissue repositories and the incorporation of correlative laboratory studies as an integral feature of clinical trials, a practice now termed “translational research.” He was part of one of the first translational research programs at Wake Forest, developing with colleagues a research team addressing white blood cell function. He was also one of the early group of researchers who pioneered the use of multiple drug regimens in the treatment of lymphoma and Hodgkin disease.

He earned his undergraduate degree from North Carolina State University and attended medical school as one of the original William Neal Reynolds Scholars. He completed an internship at the University of Virginia, and served his residency and oncology fellowship at Wake Forest Baptist Medical Center. He remained at Wake Forest for the next 32 years and served the institution in various capacities, including Active Director of the Comprehensive Cancer Center and Associate Director for Community Research and Education.

In 2012, Dr. Cooper was recognized with the Distinguished Achievement Award of the Medical Alumni Association of Wake Forest School of Medicine. He also had an interest in land and agriculture. While practicing medicine, he also enjoyed raising cattle. He converted land he owned into a sustainable tree farm, where he preserved the timber and the wildlife, and shared with the local community. In 2008, Dr. Cooper was selected as the National Tree Farmer of the Year by the American Forest Foundation.
Alliance ASCO 2015 Submission Policy

The 2014 American Society of Clinical Oncology (ASCO) Annual Meeting will take place May 29-June 2, 2015 in Chicago, IL. The deadline for submission of ASCO abstracts is February 3, 2015.

All draft abstracts from Alliance for Clinical Trials in Oncology must be submitted by January 16, 2015 to the Alliance by e-mail to Publications@AllianceNCTN.org. This deadline is firm, and is required to ensure time for central review of content, as well as review of author lists. Adherence to this guideline will assure sufficient time for the each lead investigator to submit to ASCO. All Alliance abstracts must follow this process. Independent submission of work related to the Alliance without this proper review is not permitted.

For accepted abstracts, please send the publications coordinator (Publications@AllianceNCTN.org) the acceptance notification and final accepted abstract within one (1) week after notification of acceptance from ASCO.

An Alliance abstract should contain the following information:

**Study number(s)**
- For an Alliance study X, the study number should appear in the title as “Alliance X”
- For a legacy study, the study number should appear in the title as “[Legacy Group Name] X (Alliance)” (e.g., “CALGB 40101 (Alliance)”)
- If multiple studies are involved and the title cannot accommodate all of the numbers, the study numbers must appear in the text of the abstract.

**Authors**
- The Alliance statistician must appear in the list of authors, usually as second author
- The list of authors should reflect study participation, including patient accrual and scientific input

**Affiliation and grant support**
- Provide institutional affiliation and grant/foundation support for each author

**Corresponding author**
- Provide the name and contact information of the corresponding author

### 2015 ASCO Annual Meeting: Abstract Schedule

<table>
<thead>
<tr>
<th>Event</th>
<th>Date/Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author deadline to submit abstract to Alliance for review</td>
<td>January 16, 2015</td>
</tr>
<tr>
<td>ASCO abstract submission deadline</td>
<td>February 3, 2015 / 11:59 pm EST</td>
</tr>
<tr>
<td>Author deadline to send accepted abstract to Alliance</td>
<td>One week after notification of acceptance from ASCO</td>
</tr>
<tr>
<td>ASCO meeting dates</td>
<td>May 29-June 2, 2015</td>
</tr>
</tbody>
</table>

**Questions:** For more information about the Alliance abstract submission process, contact the publications coordinator (Publications@AllianceNCTN.org).
ALLIANCE BY THE NUMBERS 2014

136
ALLIANCE NLAPS, NCORP & MAIN MEMBERS

927
NON-ALLIANCE MEMBERS (AFFILIATES)

1,063
ALLIANCE SITES

3,000
ALLIANCE NETWORK ACCRUAL

47
ALLIANCE TRIALS IN PROGRESS

120
ALLIANCE ABSTRACTS & MANUSCRIPTS PUBLICATIONS

900
ALLIANCE MEMBERS & GUESTS @FALL GROUP MEETING

44
STATES REPRESENTED BY ALLIANCE MEMBERS @FALL GROUP MEETING

44
ALLIANCE MANUSCRIPTS PUBLISHED IN HIGH-IMPACT JOURNALS (FACTOR >5)

49
STATES (PLUS DISTRICT OF COLUMBIA, PUERTO RICO & CANADA) WITH PERFORMANCE SITES IN ALLIANCE NETWORK

40
ACTIVE ALLIANCE COMMITTEES

5
ALLIANCE PROGRAMS (CENTRAL PROTOCOL OPERATIONS, STATISTICS AND DATA MANAGEMENT, TRANSLATIONAL RESEARCH, CANCER CONTROL AND AMERICAN COLLEGE OF SURGEONS CLINICAL RESEARCH) PLUS OFFICE OF THE GROUP CHAIR
Climbing Kilimanjaro to Promote – and Fund – Cancer Clinical Trials

Charles Blanke, MD, the head of one of the country’s largest cancer clinical research consortiums, will scale Mt. Kilimanjaro next February to raise awareness of the importance of clinical trials in developing better treatments for cancer patients and to help more patients enroll to studies, while at the same time raising money to help offset dwindling federal funding of such studies.

Dr. Blanke, who is now training for the Kilimanjaro climb, is a Professor of Medicine at the Knight Cancer Institute at Oregon Health & Science University and serves as chair of SWOG Cancer Research.

Supporters of the Kilimanjaro Climb for Cancer Clinical Trials campaign can take part by making a donation at swog.org/kilimanjaro, where they can watch a brief video to meet Blanke and learn more about the climb and the reasons behind it. Contributions are being taken in by SWOG’s non-profit arm, The Hope Foundation, and fully 98 percent of each donation will go directly to cancer research. Friends can also help spread the word by liking the campaign’s Facebook page at facebook.com/ClimbforCancerClinicalTrials and sharing it with others.

Future Meeting Dates

2015 Spring Group Meeting
May 14-16

2015 Fall Group Meeting
November 4-8

2016 Fall Group Meeting
November 2-5

2017 Fall Group Meeting
November 1-4

All meetings are open to all Alliance members and will be held at Loews Hotel Chicago O’Hare, 5300 N. River Road, Rosemont, IL 60018

For meeting and travel inquiries, contact Alison Lewandowski
e-mail: alewandowski@partners.org
phone: 617-525-3022